

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

BIOTRANSPLANT INC  
Form 8-K  
October 25, 2002

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2002

BIOTRANSPLANT INCORPORATED

(Exact name of registrant as specified in its charter)

DELAWARE	000-28324	04-3119555
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Building 75, Third Avenue Charlestown Navy Yard Charlestown, MA	02129
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 241-5200

N/A

-----  
(Former name or former address, if changed since last report)

Item 5. Other Events.

On October 24, 2002, BioTransplant Incorporated issued a press release announcing preliminary results from the partial analysis of Phase II clinical trial data for MEDI-507 and a delay in the clinical development timeline for MEDI-507. See the press release attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Information and

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

Exhibits.

(c) Exhibits.

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 24, 2002

BIOTRANSPLANT INCORPORATED

By: /s/ DONALD B. HAWTHORNE

-----  
Donald B. Hawthorne  
President and Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NO.

EXHIBIT

Exhibit 99.1

Press Release dated October 24, 2002